1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Cassava’s Simufilam Continues To Alienate Investors Despite Some Phase II Alzheimer’s Promise

 
• By Ayisha Sharma

The US firm is touting top-line data from an open-label Alzheimer’s disease trial as a net positive, but the lack of p-values and a declining trend in efficacy left some investors and analysts lukewarm.  

Businessman walking on animated red arrow that is pointing diagonal and downwards
Simufilam's Efficacy Has Been Declining With Each Data Release • Source: Shutterstock

Cassava Sciences, Inc.’s simufilam has shown some signs of promise in a Phase II trial in Alzheimer’s disease (AD)but concerns about lack of detail on statistical significance as well as a general downward trend in responses have dampened its shine.

Simufilam is an oral small-molecule drug candidate that aims to restore the normal shape and function of filamin A (FLNA)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 
• By Alaric DeArment

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.